A5067780934- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- Gut microbiota and health
- Tryptophan and brain disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Myeloid Leukemia Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Cell Adhesion Molecules Research
- Immune cells in cancer
- Chronic Lymphocytic Leukemia Research
- Cancer Cells and Metastasis
- Ocular Oncology and Treatments
- Ferroptosis and cancer prognosis
- Cytomegalovirus and herpesvirus research
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Extracellular vesicles in disease
- Cancer-related gene regulation
Sapienza University of Rome
2016-2025
Policlinico Umberto I
2016-2023
University of Copenhagen
2013
King's College Hospital
2013
Guy's Hospital
2013
Abstract Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only 20–30% treated patients present long term benefits. The metabolic changes occurring in gut microbiota metabolome are herein proposed as a factor potentially influencing response to immunotherapy. Methods metabolomic profiling was characterized 11 affected by non-small cell lung cancer (NSCLC) with nivolumab second-line treatment anti-PD-1 nivolumab. metabolomics analyses were performed GC–MS/SPME and 1 H-NMR...
Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% patients experience a durable benefit, while vast majority demonstrate primary or acquired resistance. Recently, indoleamine 2,3-dioxygenase (IDO) activity has been proposed as possible mechanism resistance to anti-PD-1 leading an...
// Andrea Botticelli 1, 2 , Concetta Elisa Onesti Ilaria Zizzari 3 Bruna Cerbelli 4 Paolo Sciattella 5 Mario Occhipinti 1 Michela Roberto Francesca Di Pietro Adriana Bonifacino 6 Michele Ghidini 7 Patrizia Vici 8 Laura Pizzuti Chiara Napoletano Lidia Strigari 9 Giulia D'Amati Federica Mazzuca Marianna Nuti and Marchetti Medical Oncology Department, Sant'Andrea Hospital, Rome, Italy Department of Clinical Molecular Medicine, "Sapienza" University Experimental Radiological Oncological...
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed the treatment of patients HR+/HER2- metastatic breast cancer (mBC). In this prospective study, we investigate impact CDK4/6i on immune profile mBC.Immune cell subsets were analysed using flow cytometry peripheral blood mononuclear cells (PBMCs) isolated from mBC, both before and during treatment. Regulatory T (Tregs) identified...
Dendritic cells ( DC s) sense the microenvironment through several types of receptors recognizing pathogen‐associated molecular patterns. In particular, C ‐type lectins, expressed by distinct subsets s, recognize and internalize specific carbohydrate antigen in a Ca 2+ ‐dependent manner. Targeting these is becoming an efficient strategy delivering antigens ‐based anticancer immunotherapy. Here we investigated role macrophage galactose type ‐lectin receptor MGL ), immature s (iDCs), as target...
The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available aid selection. Patients with stage IIIB–IV NSCLC receiving nivolumab at Sant'Andrea Hospital Regina Elena National Cancer Institute from June 2016 July...
Unresectable recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins that result from the alternative splicing of membrane can modulate response to cancer cells. The aim our pilot study was determine possible role comprehensive evaluation sICs in classification prognosis treatment patients with advanced disease. We evaluated several (CD137, CTLA-4, PD-1, PD-L1, PD-L2, TIM3, LAG3, GITR,...
Abstract Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint (ICIs) also been proposed treatment of mRCC encouraging results. A better understanding activity immune cells mRCC, immunomodulatory effects TKIs, characteristics defining most likely to benefit from various therapies will help optimize immunotherapeutic approaches. In this...
Abstract Background Immune checkpoint inhibitors (ICIs), administered alone or combined with chemotherapy, are the standard of care in advanced non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). Despite these treatments' success, most long-term survival benefit is restricted to approximately 20% patients, highlighting need identify novel biomarkers optimize treatment strategies. In several solid tumors, immune soluble factors, activatory CD137 + Tcells, and immunosuppressive cell...
Backgrounds. Clinical trials showed that only a subset of patients benefits from immunotherapy suggesting the need to identify new predictive biomarker resistance.. Indolamine 2,3-dioxygenase (IDO) has been proposed as mechanism resistance anti-PD1 treatment and serum kyn/trp ratio represent possible marker IDO activity. Methods. Metastatic NSCLC, RCC HNSCC treated in second line with nivolumab were included this prospective study. Baseline kynurenine tryptophan levels measured by...
Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate correlation between clinical response bevacizumab-based chemotherapy improvement immune fitness multi-treated ovarian patients. Peripheral blood mononuclear cells (PBMCs) 20 consecutive recurrent retrospectively selected have received or non-bevacizumab-based (Bev group Ctrl group, respectively) were analyzed....
Cholangiocarcinoma (CCA) is a very aggressive cancer showing the presence of high stem cells (CSCs). Doublecortin-like kinase1 (DCLK1) has been demonstrated as CSC marker in different gastroenterological solid tumors. Our aim was to evaluate vitro expression and biological function DCLK1 intrahepatic CCA (iCCA) perihilar (pCCA).Specimens surgically resected human were enzymatically digested, submitted immunosorting for specific markers (LGR5 [leucine-rich repeat-containing G protein-coupled...
Patients with non-small cell lung cancer (NSCLC) have been shown to benefit from the introduction of anti-PD1 treatment. However, not all patients experience tumor regression and durable response. The identification a string markers that are direct or indirect indicators immune system fitness is needed choose optimal therapeutic schedules in management NSCLC patients. We analyzed 34 immuno-related molecules (14 soluble checkpoints, 17 cytokines/chemokines, 3 adhesion molecules) released...
Abstract Purpose: CD137 molecule is expressed by activated lymphocytes, and in patients with cancer identifies the tumor-reactive T cells. In solid tumors, high levels of circulating CD137+ cells are associated clinical response disease-free status. Here, we examined role improvement patients' selection for immunotherapy treatment. Experimental Design: Peripheral blood mononuclear derived from 109 metastatic (66 identification cohort 43 validation cohort) were analyzed expression CD3, CD4,...
Trastuzumab's targeted therapy has become a stronghold for human epidermal growth factor receptor 2 positive breast cancer patients.This humanized monoclonal antibody binds to the extracellular juxta-membrane domain of HER2 and inhibits proliferation survival dependent cells.The ways by which this molecule exerts its action have been partially elucidated but several new mechanisms are being constantly identified.Several agents introduced that interfere with HER2.Several immunotherapy...
Abstract Background Mesenchymal stromal cells (MSCs) have been largely investigated, in the past decade, as potential therapeutic strategies for various acute and chronic pathological conditions. MSCs isolated from different sources, such bone marrow (BM), umbilical cord tissue (UCT) adipose (AT), share many biological features, although they may show some differences on cumulative yield, proliferative ability differentiation potential. The standardization of growth their functional...
Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor kinases (RTKs) involved in oncogenesis and angiogenesis. It currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), hepatocellular (HCC). Combination of with immunotherapy now treatment cancer, its efficacy being tested ongoing clinical trial prostate patients. Here, we report that may exert an immunostimulatory role by inducing immunogenic stress cells...